Long-term treatment with apremilast in hidradenitis suppurativa: A 2-year follow-up of initial responders

Pim Aarts; Allard R.J.V. Vossen; Hessel H. van der Zee; Errol P. Prens; Kelsey R. van Straalen

doi:10.1016/j.jaad.2020.08.113

Long-term treatment with apremilast in hidradenitis suppurativa: A 2-year follow-up of initial responders

Pim Aarts, Allard R.J.V. Vossen, Hessel H. van der Zee, Errol P. Prens, Kelsey R. van Straalen^*

^*Corresponding author for this work

Dermatology

Research output: Contribution to journal › Article › Academic › peer-review

17 Citations (Scopus)

Original language	English
Pages (from-to)	258-260
Number of pages	3
Journal	Journal of the American Academy of Dermatology
Volume	85
Issue number	1
DOIs	https://doi.org/10.1016/j.jaad.2020.08.113
Publication status	Published - 1 Jul 2021

Bibliographical note

Funding Information:
Funding sources: Celgene, now Amgen, provided funding in kind by providing apremilast through a compassionate use program.

Access to Document

10.1016/j.jaad.2020.08.113

Cite this

@article{f2c9c7cc44ba4200946a51de09185456,

title = "Long-term treatment with apremilast in hidradenitis suppurativa: A 2-year follow-up of initial responders",

author = "Pim Aarts and Vossen, {Allard R.J.V.} and {van der Zee}, {Hessel H.} and Prens, {Errol P.} and {van Straalen}, {Kelsey R.}",

note = "Funding Information: Funding sources: Celgene, now Amgen, provided funding in kind by providing apremilast through a compassionate use program.",

year = "2021",

month = jul,

day = "1",

doi = "10.1016/j.jaad.2020.08.113",

language = "English",

volume = "85",

pages = "258--260",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Long-term treatment with apremilast in hidradenitis suppurativa

T2 - A 2-year follow-up of initial responders

AU - Aarts, Pim

AU - Vossen, Allard R.J.V.

AU - van der Zee, Hessel H.

AU - Prens, Errol P.

AU - van Straalen, Kelsey R.

N1 - Funding Information: Funding sources: Celgene, now Amgen, provided funding in kind by providing apremilast through a compassionate use program.

PY - 2021/7/1

Y1 - 2021/7/1

UR - http://www.scopus.com/inward/record.url?scp=85105270288&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2020.08.113

DO - 10.1016/j.jaad.2020.08.113

M3 - Article

C2 - 32891782

AN - SCOPUS:85105270288

SN - 0190-9622

VL - 85

SP - 258

EP - 260

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 1

ER -

Long-term treatment with apremilast in hidradenitis suppurativa: A 2-year follow-up of initial responders

Bibliographical note

Access to Document

Other files and links

Cite this